SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

TAKECAB/VOCINTI

TAK·TAKEDA PHARMACEUTICAL CO LTD
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved and marketed
Time to market
Already marketed. Launched in Japan in February 2015. US launch via Phathom as Voquezna in late 2023. Korean launch with insurance coverage begins November 1, 2026.
Why 4/10
Vonoprazan is already approved and marketed across multiple regions with no pending US/EU regulatory decision for Takeda (US rights are licensed to Phathom). The next dated catalyst is the Korean insurance reimbursement launch on November 1, 2026, a commercial event rather than a binary regulatory decision. As a ~3% contributor to a broadly diversified ¥4.5 trillion pharma company, a commercial launch in one country will not be a standalone share-price mover for TAK.
Actionable Insight NEUTRAL

The next near-term event for the drug is the Korean national insurance reimbursement launch on November 1, 2026, announced today. This is a commercial expansion into a competitive market already dominated by three Korean-developed P-CABs (K-CAB, Fexuclue, Jaqbo). For a diversified pharma like Takeda, the stock move from vonoprazan-specific news is likely to be small; watch Phathom Pharmaceuticals (PHAT) for US Voquezna sales trajectory and the Phase 2 EoE readout expected late 2026/early 2027 instead.

Price Chart

Loading chart...

Executive Summary

Vonoprazan (sold as TAKECAB in Japan, VOCINTI in other Asian markets, Voquezna in the US) is a first-in-class potassium-competitive acid blocker (P-CAB) discovered by Takeda. First approved in Japan in 2014, it is now marketed across Asia and Latin America by Takeda and in the US/Europe by partner Phathom Pharmaceuticals. The drug generated JPY 143.7 billion (~$950M) in sales for Takeda in FY2025 (up 9.9%), driven by Japan and China. Today (October 29, 2026), Takeda announced Korean insurance coverage for Vocinti starting November 1, entering a competitive market against established Korean P-CABs. Vonoprazan is an important growth product within Takeda's portfolio but represents roughly 3% of total company revenue. For Takeda investors, this is a steady commercial franchise with no imminent binary regulatory catalyst.

How It Works

Vonoprazan is a potassium-competitive acid blocker (P-CAB), a class of stomach-acid reducer that works by blocking the proton pump (the final step of acid production) in stomach-lining cells. Unlike standard proton-pump inhibitors (PPIs) that take days to reach full effect, P-CABs start working within hours and provide more consistent acid suppression regardless of when food is taken. It is taken as a once-daily tablet to treat acid reflux, erosive esophagitis, gastric ulcers, and H. pylori infection.

Trial Status

Vonoprazan is already approved in over 30 countries for acid-related diseases. Phathom is running a Phase 2 trial (pHalcon-EoE-201) in eosinophilic esophagitis with topline results expected late 2026 or early 2027, but this is a Phathom (PHAT) program, not a Takeda program. No late-stage pivotal trials remain for Takeda's own indications.

The Two-Sided Case

▲ Bull Case5
Vonoprazan is a first-in-class P-CAB, the first major innovation in acid-reducing therapy in over 30 years, offering rapid and sustained acid suppression compared to standard PPIs.
Takeda's TAKECAB/VOCINTI franchise revenue grew 9.9% in FY2025 to JPY 143.7 billion (~$950M), driven by strong demand in Japan and China.
Korean national insurance reimbursement starting November 1, 2026 opens a new market; Korea's P-CAB market is expected to exceed 400 billion won (~$285M) in 2026.
Institutional accumulation signals were positive, with FMR LLC adding 34.9% and Millennium Management and Qube Research taking new positions in Q2 2026.
Analyst consensus shows 14 Buy/Strong Buy ratings vs 7 Hold and 0 Sell, with a mean price target of ~$22.61 implying ~12% upside from the recent $20.15 close.
▼ Bear Case5
Intense competition in Korea from three established locally-developed P-CABs (K-CAB, Fexuclue, Jaqbo) with K-CAB alone posting ~$570M in prescriptions since 2019, making it hard for late-entrant Vocinti to gain significant share.
Takeda's compound patent for vonoprazan nears expiration in 2027 in key markets, and over 20 Korean generic manufacturers are preparing to enter the P-CAB space.
Vonoprazan contributes roughly 3% of Takeda's total revenue (JPY 143.7B out of ¥4.51T), so even strong sales growth has limited impact on the overall Takeda stock.
Takeda's US/European rights are licensed to Phathom Pharmaceuticals, so Takeda captures no direct upside from the fast-growing US Voquezna franchise.
Insider selling was concentrated in August-September 2026, with the CEO and President of R&D among those selling shares.

Upcoming Catalysts

  • Korean national insurance reimbursement launch for Vocinti on November 1, 2026
  • Potential generic competition as substance patent nears expiry in 2027
  • Phathom's Phase 2 EoE readout (late 2026/early 2027) could indirectly support the drug class

Source Filing

The SecBot filing or press-release report that triggered this drug report:

TAKEDA PHARMACEUTICAL CO LTD 6-K TAK ·Originating report

Sources · 11

Hover a chip for the title
1 en.sedaily.com2 takeda.com3 growthmarketreports.com4 adis.springer.com5 en.wikipedia.org6 investors.phathompharma.com7 businesskorea.co.kr8 biz.chosun.com9 takeda.com10 drugs.com11 investors.phathompharma.com